FDA Disperses $22 Million for Rare Diseases.
The FDA has awarded 15 grants totaling $22 million over 4 years through its Orphan Products Clinical Trials Grant Program. One third of the awards will support ongoing clinical trials of therapies for rare cancers for which there are few approved or effective treatment options.